Long-term Outcome of Children with Acute Lymphoblastic Leukemia Treated with IC-BFM2002 Regimen

Gholamreza Bahoush1 *

1Department of Pediatrics, Ali-Asghar Children Hospital, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Background: Changes in pediatric chemotherapy regimens over the last three decades have introduced a variety of protocols to increase the survival of patients with acute lymphoblastic leukemia (ALL). Intercontinental Berlin-Frankfort-Munich (IC-BFM) 2002 is one of the protocols widely used in countries that could not perform minimal residual disease by polymerase chain reaction (MRD PCR) method. Evaluation the results of these regimens is very effective in improving their quality.

Materials and Methods: Children with newly diagnosed ALL in Ali Asghar Children's Hospital were randomly divided into two groups. Patients in both groups underwent chemotherapy according to IC-BFM 2002 protocol. Patients were divided into two groups based on the type of reinduction regimen, so that patients in-group A received protocol II and patients in-group B received protocol III as a reinduction regimen. Then demographic information and patient outcome were statistically analyzed with SPSS 23.

Results: Sixty-three patients were included in the study. There were 32 patients in-group A (18 boys and 14 girls) and 31 patients in-group B (11 boys and 20 girls). The number of high-risk patients was higher in-group A, but this difference was not statistically significant. The recurrence

*Corresponding author: E-mail: Bahoush.gh@iums.ac.ir;
1. INTRODUCTION

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the outcome of has significantly improved over the past 40 years [1]. This is due to the redoubled efforts of medical research teams around the world. One of the oldest and most famous of these groups is the International Berlin-Frankfurt-Münster study group (I-BFM-SG). It has over 30 member countries, and in the form of various working committees, it conducts research on various basic and clinical aspects of pediatric leukemia and lymphoma. Over the past 30 years, this group has introduced several protocols to improve the outcome of children with ALL, including ALL BFM-83, BFM-90, BFM-95, and finally BFM2002 and BFM2009 [2-7]. BFM and AIEOP (Associazione Italiana Ematologia Oncologia Pediatria) groups showed that measurement of minimal residual disease (MRD) by polymerase chain reaction (PCR) at weeks 5 and 12 of the protocol is very useful in identifying high-risk patients who are not detectable by bone marrow morphology [8-11]. Because this method is expensive and its technology does not exist in most developing and low-income countries, BFM used peripheral blood smear morphology examination on day 8 and bone marrow aspiration morphology examination on days 15 and 33, instead of using PCR-MRD, and introduced the IC-BFM 2002 protocol for these countries [10,12].

On the other hand, evaluation the outcome of children with ALL treated with this treatment regimen in developing countries such as Iran can be very helpful in improving the treatment protocol in the coming years. Therefore, in this study, we report the results of the treatment of these patients from Ali-Asghar Children hospital.

2. MATERIALS AND METHODS

A retrospective case-control analytical study from 2009 to 2015, in which children with B-precursor ALL (1-16 years old) referred to Ali Asghar Children's Hospital in Tehran of Iran University of Medical Sciences after confirmation of diagnosis with BMA and flow cytometry. All patients were included into two groups and treated with IC-BFM 2002 chemotherapy regimen. As you can find in Table 1, patients in-group A routinely received protocol II as a reinduction during the treatment (one time for the standard and intermediate risk groups and two times for the high-risk group). While patients in-group B received protocol III as reinduction (twice for standard and intermediate risk groups and three times for high-risk group). Then demographic data and risk groups defined according to IC-BFM 2002 protocol for each patient were extracted.

2.1 Data Analysis

Patients’ information was entered into SPSS v23.0. Descriptive data were analyzed by descriptive tests. The Kaplan-Meier test was used to determine event-free survival (EFS). Log-Rank method was employed to measure the survival rate and P-value less than 0.05 was considered as significant. Based on the median follow-up months, the estimated long term EFS values were determined for patients.

3. RESULTS

Sixty-three patients were included in the study. All patients in the study had B-precursor ALL and none of them had t (4; 11) or t (9; 22). Thirty-two patients were in-group A (18 boys and 14 girls) and 31 patients were in-group B (11 boys and 20 girls). The number of boys was higher in-group A, but this difference was not statistically
significant \(P = 0.08\) with Odd ratio = 2.33 (0.84-6.44). There was no statistically significant difference between the two groups in terms of mean age at diagnosis and initial WBC (Table 2).

The number of patients older than 10 years at the time of diagnosis was 17.5 in total and about 8.3% of the patients in the study had an initial WBC count greater than 50,000/μl and there was no significant difference between the two groups, neither of the two groups had CNS involvement at the time of diagnosis. The number of high-risk patients was higher in-group A, but this difference was not statistically significant (Fig. 1).

### Table 1. IC-BFM 2002 Protocol used for all enrolled patients

| Treatment element/drug          | Treatment method | Single dose | Per-day dose | Days of administration |
|---------------------------------|------------------|-------------|--------------|------------------------|
| **Induction**                   |                  |             |              |                        |
| Protocol I' (SR BCP-ALL only)   | PO               | 60 mg/m²    | 1-28b        |                        |
| Prednisone                      | IV               | 1.5 mg/m²   | 8, 15, 22, 29|                        |
| Vincristine                     | PI over 1 hour   | 30 mg/m²    | 8, 15, 22c, 29c|                      |
| Daunorubicin                    | PI over 1 hour   | 5,000 IU/m² | 12, 15, 18, 21, 24, 27, 30, 33|        |
| L-asparaginase                  | IT               | 12 mg/d     | 1, 12, 33    |                        |
| Methotrexate                    | PI over 1 hour   | 1,000 mg/m² | 40, 75       |                        |
| **Phase 2**                     |                  |             |              |                        |
| Cyclophosphamide, Cytarabine    | IV               | 75 mg/m²    | 47-50, 54-57, 61-64, 68-71, 41-46, 51-53, 58-60, 65-67, 72-74, 76-81|        |
| GCSF                            | SC               | 5 μg/kg     | 47-50, 54-57, 61-64, 68-71, 41-46, 51-53, 58-60, 65-67, 72-74, 76-81|        |
| 6-mercaptopurine                |                  | PO          | 60 mg/m²     | 40-68                  |
| Methotrexate                    | IT               | 12 mg/d     | 54, 68       |                        |
| **Consolidation**               |                  |             |              |                        |
| Protocol mM (only BCP-ALL, SR/IR)| PO               | 25 mg/m²    | 1-56         |                        |
| 6-mercaptopurine                |                   |             |              |                        |
| Methotrexate                    | PI over 24 hour  | 2,000 mg/m² | 8, 22, 36, 50|                        |
| GCSF                            | SC               | 5 μg/kg     | 8, 22, 36, 50|                        |
| Methotrexate                    | IT               | 12 mg/d     | 1-56         |                        |
| Protocol M (only T-ALL, SR/IR)  |                   |             |              |                        |
| 6-mercaptopurine                | PO               | 25 mg/m²    | 8, 22, 36, 50|                        |
| Methotrexate                    | PI over 24 hours | 5,000 mg/m² | 8, 22, 36, 50|                        |
| Methotrexate                    | IT               | 12 mg/d     | 1-21b        |                        |
| **Delayed intensification**     |                  |             |              |                        |
| Protocol II'                    | PO/IV            | 1.5 mg/m²   | 8, 11, 15, 18|                        |
| Dexamethasone                   | IV               | 30 mg/m²    | 8, 15, 22, 29|                        |
| Vincristine                     | PI over 1 hour   | 10,000 IU/m²| 8, 15, 22, 29|                        |
| Doxorubicin                     | PI over 1        | 10,000 IU/m²| 8, 15, 22, 29|                        |
| L-asparaginase                  | PI over 1        |             | 8, 15, 22, 29|                        |
| Treatment element/drug       | Treatment method | Single dose | Per-day dose | Days of administration |
|------------------------------|------------------|-------------|--------------|------------------------|
| **Phase 2: Cyclophosphamide** |                  |             |              |                        |
| Cytarabine                   | Pl over 1 hour IV| 1,000 mg/m² |              | 36-46, 50-53           |
| 6-thioguanine                | PO               | 75 mg/m²    |              | 36-49                  |
| Methotrexate                 | PO/IT            | 12 mg²      | 60 mg/m²     | 43, 50                 |
| Interim maintenance therapy  | Methotrexate     | PO          | 20 mg/m²     |                        |
| 6-mercaptopurine             | PO               | 50 mg/m²    |              |                        |
| Maintenance therapyh        | Methotrexate     | PO          | 20 mg/m²     |                        |
| 6-mercaptopurine             | PO               | 50 mg/m²    |              |                        |

Table 2. Comparison between two groups in terms of age at diagnosis, duration of follow-up and initial WBC

| Groups     | N  | Mean  | Std. deviation | Std. error | P value |
|------------|----|-------|----------------|------------|---------|
| Age at diagnosis (mo) | A  | 32    | 63.28          | 45.821     | 8.100   |
|            | B  | 31    | 65.47          | 41.355     | 7.428   | 0.84    |
| Duration of follow-up (mo) | A  | 32    | 113.81         | 23.788     | 4.205   |
|            | B  | 31    | 97.45          | 34.304     | 6.161   | 0.03    |
| Initial WBC | A  | 32    | 11906.67       | 16885.189  | 3082.800|
|            | B  | 31    | 21713.33       | 30742.902  | 5612.860|

Fig. 1. Compassion between two groups for distribution of patients with different risk groups (SR= standard risk; IR= intermediate risk; HR= high risk)

In terms of response to prednisolone during the first week of remission induction period, 17.5% of all patients had prednisolone poor response and there was no significant difference between the two groups in this regard. The recurrence rate (relapses) in group B patients was about seven times higher than the recurrence rate in group A patients, and this difference was statistically significant (Fig. 2). In group A there was no early relapse (recurrence in the first 18 months after
diagnosis). About half of the recurrences in group B occurred as early relapse and the rest as late relapse (recurrence after 18 months from diagnosis); Of course, this difference was not statistically significant (Fig. 3).

The most common recurrence was in bone marrow, which occurred in-group B patients. CNS recurrence occurred in only two patients (Table 3).

The median follow-up of all enrolled patients was about 112 months. According to this finding, the 5-yr EFS of all patients studied was 88.90 ± 8.00% with 95% confidence interval (95% CI), (Fig. 4).
Table 3. Comparison between the two studied groups in terms of relapse site

| Groups | Count | % within Groups | no relapse | BM | CNS | BM & CNS | Total |
|--------|-------|----------------|------------|----|-----|----------|-------|
| A      | 31    | 96.9%          | 0          | 1  | 0   | 32       |
| B      | 25    | 80.6%          | 4          | 1  | 1   | 31       |
| Total  | 56    | 88.9%          | 4          | 2  | 1   | 63       |

BM = Bone Marrow; CNS = Central Nervous System

In terms of the effect of gender on the outcome of all enrolled patients, the 5-yr EFS was 94.10 ± 8.00% (95% CI) for girls and 82.80 ± 14.00% (95% CI) for boys; but this difference was not statistically significant. The level of 5-yr EFS was 96.90 ± 6.20% (95% CI) for group A and 80.60 ± 14.20% (95% CI) for group B and this difference was statistically significant (Fig. 5).

4. DISCUSSION

Chemotherapy has long been the mainstay of treatment for children with ALL, and various research groups around the world have developed a variety of chemotherapy regimens with varying implications. One of the oldest of these protocols is provided by the BFM group and is in fact one of the most popular chemotherapy regimens in the world for this group of patients. A comparison of popular chemotherapy regimens for children with ALL presented by SIOP in 2010 found that the BFM protocol had one of the best outcomes for this group of patients by 2000 [13]. Due to the increasing use of MRD in improving the outcome of these patients in the first decade of the 21st century, the BFM group presented its new protocol in 2002 under a clinical trial based on the main use of MRD results. Due to the inability of developing countries to perform accurate MRD, this group presented another protocol based on peripheral blood and bone marrow morphological findings during a treatment called IC-BFM 2002. In this article, we present and analyze the outcome of patients treated with this treatment regimen who referred to one of the most prestigious and oldest pediatric oncology centers in Iran, and compared to the results of other countries, especially developed countries, we achieved significant results.

In a study presented in 2016 from Czechoslovakia, the estimated 5-yr EFS of 24 patients was about 83% [14]. An initial study reported from IC-BFM 2009 by Nath et al. in 2019 showed an increase in disease-free survival of 88% [7]. Evaluating the results of other protocols presented by well-known research groups also shows the results of IC-BFM 2002 comparable. Gaynon et al. in 2010
reported the outcome of children with B-precursor ALL treated with CCG-1900 regimen at 5-yr EFS 82% for the standard risk group and 70% for the high-risk group [15]. In a 2010 study, Salzer et al reported that the rate of 10-yr EFS in patients with standard risk (NCI standard risk with DNA index ≤ 1.16 or lacking trisomies 4 and 10; or NCI higher risk with DNA index > 1.16 or trisomies 4 and 10) B-precursor ALL treated with the ALinC16 chemotherapy regimen was about 73%, and the rate was about 86% for the low-risk group [16]. In 2013, a report was published from Egypt on the outcome of 14 children with T-cell ALL treated with the CCG1991 protocol had a 5-yr EFS of 77% [17]. In 2016, Trehan et al. reported a 65% EFS outcome of treatment using the UKALL 2003 (known as protocol 2) chemotherapeutic regimen [18]. In comparison to all these results and despite the small number of patients in the high-risk group in our study, the results obtained are not only comparable to other developed countries, but as a developing country is quite brilliant and thought provoking.

In 2007, Zając et al. presented the results of the treatment of 41 children with ALL treated with this protocol with a very brilliant result of estimated 5-yr EFS of about 92% [19]. Federico G. et al. presented a report from a very low-income country, Guatemala, on 787 children treated with IC-BFM 2002 protocol, despite the fact that about 450 patients were in the intermediate risk group and 177 patients were in the high-risk group. Their estimated 5-yr EFS was about 56% [20]. In 2012, Gao et al. described the treatment outcome of 92 Chinese children with ALL treated with IC-BFM 2002 with a 6-yr EFS of approximately 75.5% [21]. However, the first valid report published by the BFM group in early 2014 included 5060 patients treated with IC-BFM 2002. Of these, 26.5% were at the age of diagnosis more than 10 years, about 20% in all initial WBC patients had more than 50,000/μl, 13% T-cell type, 2.8% t(9;22) and 1% t(4;11). Under these conditions, the 5-yr EFS of all patients was about 74%². Interestingly, patients treated with protocol II as a reinduction of EFS were better than patients treated with Protocol III in our study, which was statistically significant. This was confirmed by doing not use of Protocol III in IC-BFM 2009 for standard and intermediate risk groups and using only Protocol II [22]. On the other hand, CNS recurrence due to the use of high dose Methotrexate at 2 g/m² for four consecutive cycles has been minimized and its increase to 5 g/m² in four consecutive cycles for non-high-risk groups does not seem reasonable. Of course, our study with a limited number of samples may not be a definitive answer to this question.

5. CONCLUSION

The IC-BFM2002 protocol seems to be an appropriate treatment regimen with acceptable outcomes for children with ALL in developing countries, a workable protocol with significant consequences. Protocol II seems to be suitable for reinduction and increasing the MTX dose may not be necessary for non-high-risk groups.
CONSENT AND ETHICAL APPROVAL

Patients’ written consent has been collected and preserved by the author(s). Patient information was only available to the executor and the name of the patient remained confidential. Research team members were aware of the details of Helsinki statement about ethic principles in medical research and were strictly committed to follow them in this study. This project was approved at the Ethics Committee of the University of Medical Sciences.

ACKNOWLEDGEMENTS

We are deeply indebted to professor nojomi for his statistical work conducted skillfully. We are also grateful to staff of the oncology department of the ali asghar hospital for their assistance in planning and performing this study.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Ching-Hon Pui and William E. Evans: A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Semin Hematol. 2013;50(3):185–196. DOI:10.1053/j.seminhematol.2013.06.007
2. Jan Stary, Martin Zimmermann, Myriam Campbell, Luis Castillo, Eduardo Dibar, Svetlana Donska, Alejandro Gonzalez, Shai Izraeli, Dragana Janic, Janez Jazbec, Josip Konja, Emilia Kaiserova, Jerzy Kowalczyk, Gabor Kovacs, Chi-Kong Li, Edina Maqyarosy, Alexander Popa, Batia Stark, Yahia Jabali, Jan Trka, Ondrej Hrusak, Hansjoerg Riehm, Giuseppe Masera, and Martin Schrappe: Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intentional Trial ALL IC-BFM. J Clin Oncol. 2002;32:174-184; DOI: 10.1200/JCO.2013.48.6522
3. Riehm H, Reiter A, Schrappe M, et al: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83) [in German]. Klin Pa¨ Diatr. 1987;199:151-160.
4. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90—German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
5. Mo¨ ricke A, Reiter A, Zimmermann M, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.
6. Mo¨ ricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265-284.
7. Uttam Kumar Nath, DM, Debranjani Chattopadhyay, Anamika Bahl, Sudeep Vaniyath, Rituparna Chetia, Ashok K Rajoreya: Encouraging Results with ALL IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study from India. Blood. 2019;134 (Supplement_1): 5118. Available:https://doi.org/10.1182/blood-2019-127985
8. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients on the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-3214.
9. Flohr T, Schrauder A, Cazzaniga G, et al: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771-782.
10. Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia. 2008;22(5):989-997.
11. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011; 118(8):2077-2084.
12. Martin Schrappe: Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program. 2012;2012:137-42. DOI: 10.1182/asheducation-2012.1.137.

13. Martin Schrappe, Martin Stanulla: Current Treatment Approaches in Childhood Acute Lymphoblastic Leukemia. SIOP EDUCATION BOOK 2010, 42nd Congress of the International Society of Paediatric Oncology Boston, USA; 2010.

14. Volejnikova J, Jarosova M, Pospislíva D, Novak Z, Vrbkova J, M Hajduch, Hajduch M, Mihal V: Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: a retrospective single-center study from Olomouc, Czech Republic. Neoplasma. 2016;63(3):456-461. DOI: 10.4149/316_150910n482

15. PS Gaynon, AL Angiolillo, WL Carroll, JB Nachman, ME Trigg, NH Sather, SP Hunger and M Devidas for the Children’s Oncology Group, Arcadia CA, USA: Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children’s Oncology Group Report. Leukemia. 2010;24:285–297. DOI: 10.1038/leu.2009.262.

16. Wanda L. Salzer, Meenakshi Devidas, William L. Carroll, Naomi Winick, Jeanette Pullen, Stephen P. Hunger, and Bruce A. Camitta: Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children's Oncology Group. Leukemia. 2010;24(2):355–370. DOI: 10.1038/leu.2009.261

17. Azza A.G. Tantawy, Farida H. El-Rashidy, Iman A. Ragab, Osama A. Ramadan & Maha M. El-Gaafary: Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: A challenge for limited health resource countries. Hematology. 2013;18:4:204-210. DOI: 10.1179/1607845412Y.0000000061.

18. Amita Trehan, Deepak Bansal, Neelam Varma, Ajay Vora: Improving outcome of acute lymphoblastic leukemia with a simplified protocol: report from a tertiary care center in north India. Pediatric Blood and Cancer. 2017;64(4).

19. Olga Zajac, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak: Comparison of treatment results in children with non-high risk acute lymphoblastic leukaemia treated according to ALL-BFM 90 and ALL-IC BFM 2002 regimens – single centre preliminary experience. Rep Pract Oncol Radiother. 2007;12(5):283-288.

20. Federico G. Antillon, Jessica G. Blanco, Patricia D. Valverde, Mauricio Castellanos, Claudia P. Garrido, Veronica Giron, Tomas R. Letona, Emilia J. Osorio, Dyna A. Borrayo, Ricardo A. Mack, Mario A. Melgar, Rodolfo Lorenzana, Raul C. Ribeiro, Monika Metzger, Valentino Conter, Emanuela Rossi, and Maria Grazia Valsecchi: The Treatment of Childhood Acute Lymphoblastic Leukemia in Guatemala: Biologic Features, Treatment Hurdles, and Results. Cancer; 2017. DOI: 10.1002/cncr.30257

© 2020 Bahoush: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: http://www.sdiarticle4.com/review-history/64265